GRI Bio, Inc.
Advancing NKT cell modulators for inflammatory, fibrotic, and autoimmune diseases.
GRI | NDAQ
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 2223 AVENIDA DE LA PLAYA, 92037 LA JOLLA
- Website:
- https://www.gribio.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
GRI Bio, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing therapies for inflammatory, fibrotic, and autoimmune diseases. The company is advancing an innovative pipeline of Natural Killer T (NKT) cell modulators. This approach targets earlier key steps in the inflammatory cascade, aiming to interrupt disease progression and fundamentally change how these conditions are treated.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all GRI Bio, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for GRI Bio, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for GRI Bio, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
